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Objectives
The aim of the study was to assess, among people living with HIV, knowledge of their latest HIV
viral load (VL) and CD4 count.
Methods
Agreement between self-report and clinic record was assessed among 2771 HIV-diagnosed
individuals on antiretroviral treatment (ART) in the UK Antiretrovirals, Sexual Transmission Risk
and Attitudes Study (2011–2012). A confidential self-completed questionnaire collected
information on demographic, socioeconomic, HIV-related and health-related factors. Participants
were asked to self-report their latest VL [undetectable (≤ 50 copies/mL), detectable (> 50 copies/
mL) or “don’t know”] and CD4 count (< 200, 200–350, 351–500 or > 500 cells/lL, or “don’t
know”). Latest clinic-recorded VL and CD4 count were documented.
Results
Of 2678 participants on ART, 434 (16.2%) did not accurately report whether their VL was undetectable.
Of 2334 participants with clinic-recorded VL ≤ 50 copies/mL, 2061 (88.3%) correctly reported
undetectable VL; 49 (2.1%) reported detectable VL; 224 (9.6%) did not know their VL. Of 344 participants
with clinic-recorded VL > 50 copies/mL, 183 (53.2%) correctly reported detectable VL; 76 (22.1%)
reported undetectable VL; 85 (24.7%) did not know their VL. Of 2137 participants who reported
undetectable VL, clinic-recorded VL was ≤ 50 copies/mL for 2061 (96.4%) and <1000 copies/mL for 2122
(99.3%). In analyses adjusted for gender/sexual orientation, ethnicity, age and time since starting ART,
factors strongly associated with inaccurate self-report of VL (including “don’t know”) included
socioeconomic disadvantage [prevalence ratio (95% CI) for “not” vs. “always” having enough money for
basic needs: 2.4 (1.9, 3.1)], poor English fluency [3.5 (2.4, 5.1) vs. UK born], nondisclosure of HIV status
[1.7 (1.3, 2.1)], ART nonadherence [2.1 (1.7, 2.7) for three or more missed doses vs. none in the past
2 weeks] and depressive symptoms (PHQ-9 score ≥ 10) [1.9 (1.6, 2.2)]. Overall, 612 (22.9%) of 2667
participants on ART did not accurately self-report whether or not their CD4 count was ≤ 350 cells/lL.
Conclusions
There is a high level of accuracy of a self-report of undetectable VL in people on ART in the UK.
Overall, accurate knowledge of personal VL level varied according to demographic, socioeconomic,
HIV-related and health-related factors. Active identification of people who may benefit from
increased levels of support and engagement in care is important.
Correspondence: Dr Janey Sewell, UCL Department of Infection and Population Health, Royal Free Hospital, London NW3 2PF, UK.
e-mail: j.sewell@ucl.ac.uk
*See Appendix.
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Introduction
Advances in antiretroviral therapy (ART) have resulted in
greatly reduced mortality among people living with HIV
[1,2], such that life expectancy for HIV-positive individu-
als with access to treatment now approaches that of the
general population [3]. International [4–6] and UK [7]
guidelines recommend that patients are involved in
decision-making about HIV care and treatment. For this
to be achieved, patients require adequate knowledge of
their HIV-related health and treatment goals, and are
dependent on health care professionals providing and dis-
cussing the relevant information.
Reviewing laboratory markers such as CD4 counts and
HIV viral load (VL) in conjunction with a patient is now
common practice amongst HIV health care providers. Pre-
vious studies have suggested that providing health-related
knowledge to people with HIV infection may improve
adherence and treatment outcomes, as well as benefitting
the patienthealth care provider relationship [8–10]. Fur-
thermore, as increasing evidence shows that a suppressed
HIV VL greatly reduces the risk of onward transmission of
HIV to sexual partners [11–17], people with HIV infection
may use their VL results to make decisions on condomless
sex. Therefore, in this context, it is critical that individuals
have correct self-knowledge of their latest VL result.
Little is known about the accuracy of individuals’
knowledge of their own HIV biomarker status, or whether
socioeconomic and other factors impact on such knowl-
edge. In particular, there have been no studies assessing
the accuracy of self-report of VL status among people liv-
ing with HIV in the UK. Despite access to free HIV care in
the UK via the National Health Service, recent results from
the Antiretrovirals, Sexual Transmission Risk and Attitudes
(ASTRA) study indicated that socioeconomic disadvantage
was associated with a substantially increased probability of
virological nonsuppression and virological rebound among
people on treatment for HIV infection in the UK [18]. In
this study, we used data from ASTRA to investigate the
ability of individuals on ART to correctly report their HIV
VL level and CD4 count level, by comparing self-report
with the clinic-recorded value. We also assessed the associ-
ation of demographic, socioeconomic, HIV-related and
health-related factors with inaccurate reporting of HIV VL
level.
Methods
Study design and procedures
ASTRA is a cross-sectional questionnaire study that
recruited people with diagnosed HIV infection from eight
HIV out-patient clinics in the UK between February 2011
and December 2012 [19]. The time period allocated for
recruitment in each clinic was of sufficient duration that
infrequent clinic attendees would be included in those
invited to participate. Exclusion criteria were as follows:
age < 18 years; unable to understand the study question-
naire (available in English or French) because of language
or cognitive difficulties; too ill or distressed to complete
the questionnaire. Participants self-completed a confiden-
tial paper questionnaire that included items on demo-
graphics (gender/sexual orientation; age; ethnicity),
socioeconomic factors (UK birth/English fluency; educa-
tion; employment; housing; financial hardship; support-
ive network assessed by a modified version of the Duke
Functional Social Support questionnaire[18,20]), HIV-
related factors (stable partner and their HIV status; dis-
closure of HIV status; ART use; ART start date; ART
adherence), health-related factors (symptoms of depres-
sion and anxiety as assessed by the Patient Health Ques-
tionnaire, 9 item scale [PHQ-9] [21] and the Generalized
Anxiety Disorder 7 item scale [GAD-7] [22], respectively);
treatment for depression.
Participants who reported that they had ever started
ART were asked to report the value of their VL from the
last time they received their test results, with three
options: “50 copies/mL or less (‘undetectable’ or ‘sup-
pressed)”; “more than 50 copies/mL (‘detectable’ or
‘raised’)”; or “don’t know”. All participants were asked to
report their last CD4 count result, with five options; “less
than 200”; “200–350”; “351–500”; “more than 500”; or
“don’t know/can’t remember”. For all participants, the
study recruiter documented, from clinic records, the latest
VL and CD4 count laboratory results that were available
to the participant at the time the questionnaire was
issued. Therefore, information on VL and CD4 levels was
available both from the participant self-report and from
the clinic record.
Agreement between self-report and clinic record for
VL and CD4 was assessed only among participants who
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reported currently taking ART. Accurate self-report was
defined as agreement between participant self-report
and clinic record that the latest VL was either
≤ 50 copies/mL or > 50 copies/mL. Inaccurate self-
report was defined as either disagreement between self-
report and clinic record on the level of VL, or a
response of “don’t know” to the question on VL level.
Participants who had no clinic-recorded VL, whose
clinic-recorded VL was dated after the questionnaire
issue date, or who gave no response to the question on
VL level were excluded from the analysis. Similarly,
accuracy of reporting CD4 count was defined as agree-
ment between participant self-report and clinic record
that the latest CD4 count was > 350 or ≤ 350 cells/lL.
Inaccurate self-report was defined as indicating a dif-
ferent CD4 count category from that of the clinic-
recorded CD4 count, or a response of “don’t know”.
Analysis of factors associated with inaccurate self-
report was carried out for VL only, as it was posited
that, among those on ART, VL may be monitored more
regularly than CD4 count. In addition, knowledge of
VL level is of particular importance in relation to deci-
sion-making around sexual behaviour.
Statistical analysis
Agreement between participant self-report and clinic
record for VL level and CD4 level was assessed among
participants on ART. In order to examine the associations
of demographic, socioeconomic, HIV-related and health-
related factors with inaccurate self-report of VL level,
modified Poisson regression models with robust standard
errors were used to produce unadjusted and adjusted
prevalence ratios (PRs) with 95% confidence intervals
(CIs) [23]. In multivariable analyses, each factor was con-
sidered in a separate model and adjusted only for: gender/
sexual orientation [men who have sex with men (MSM),
heterosexual men and women], age group (< 30, 30–39,
40–49, 50–59, ≥ 60 years, and missing), ethnicity (white,
black African, black other, and other/
missing) and time since first starting ART group
(≤ 6 months, 6 months to 1 year, 1–2 years, 2–5 years,
5–10 years, > 10 years, and missing). Results were similar
when cases with missing values for age and time since
starting ART were excluded from analysis. Further adjust-
ment for (or stratification by) clinical centre had little
effect on associations; associations unadjusted for clinical
centre are presented. In a separate sensitivity analysis,
participants who gave no response to the question on
self-reported VL level were included in the “disagreement”
category (inaccurate self-report) rather than being
excluded.
Results
In total, 3258 patients completed a study questionnaire,
of 5112 invited to participate (response rate of 64%). Of
3202 participants with ART information, 2771 (86.5%)
were on ART, 366 were ART na€ıve, and 65 had previ-
ously taken ART but were not on ART at the time of
the questionnaire. Of 2771 participants on ART, 1891
(68.2%) were MSM, 547 (19.7%) were women and 333
(12.0%) were heterosexual men (Table 1). The mean age
was 46.1 [standard deviation (SD) 9.4] years. The sample
was predominantly of white ethnicity (n = 1894; 68.4%),
with 533 (19.2%) being of black African ethnicity, 94
(3.4%) of black Caribbean or black other ethnicity, and
250 (9.0%) of other or missing ethnicity. Forty-three per
cent of participants (1155 of 2684) were not born in the
UK, of whom just over a fifth (256; 22.2%) reported not
being fluent in spoken English. Overall, 41.4% of partic-
ipants (1115 of 2696) were educated to degree level or
above and 55.9% (1509 of 2699) were in full or part-
time employment. Less than half of participants (43.8%)
reported “always” having enough money for basic needs.
The majority of participants (1689 of 2681; 63.0%) had
started ART 5 or more years ago; 6.2% started in the
past 6 months and 30.8% started between 6 months and
5 years ago. In terms of self-reported non-adherence:
25.0% (688 of 2756) reported having missed at least
one dose of ART in the previous 2 weeks, and 17.2%
(474 of 2757) reported having missed two or more con-
secutive days of ART on at least one occasion in the
past 3 months.
Agreement between self-reported and clinic-recorded
VL
Among the 2771 participants on ART, the clinic-recorded
VL was not documented for 18 participants, and was
dated after the questionnaire issue for a further 11 partic-
ipants. In addition, 64 individuals did not provide a
response to the question on self-reported VL. Among the
remaining 2678 participants, 2334 (87.2%) had clinic-
recorded VL ≤ 50 copies/mL. Self-reported VL was as fol-
lows: 2137 (79.8%) participants reported VL ≤ 50 copies/
mL, 232 (8.7%) reported VL > 50 copies/mL, and 309
(11.5%) responded “don’t know” (Table 2a). In terms of
agreement, of the 2334 participants with a clinic
VL ≤ 50 copies/mL, a high proportion (88.3%; n = 2061)
correctly self-reported undetectable VL; 49 (2.1%) incor-
rectly self-reported that their VL was detectable, while
224 (9.6%) did not know their latest VL. Of the 344 par-
ticipants with clinic-recorded VL > 50 copies/mL, 183
(53.2%) correctly self-reported detectable VL; however,
© 2016 The Authors.
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Table 1 Demographic, socioeconomic, HIV-related and health-related factors, and associations with inaccurate self-report of clinic viral load
level, among 2771 HIV-diagnosed participants on antiretroviral therapy (ART)
Prevalence (N = 2771)*
Inaccurate self-report of clinic
viral load† (n/N = 434/2678)‡ Unadjusted PR and 95% CI§ Adjusted PR and 95% CI§
N % n/N Row % PR 95% CI P-value PR 95% CI P-value
Gender/sexual orientation (N = 2771)
MSM¶ 1891 68.2 225/1852 12.1 1 1
Heterosexual men 333 12.0 91/312 29.2 2.4 1.9, 3.0 1.8 1.4, 2.4
Women 547 19.7 118/514 23.0 1.9 1.5, 2.3 < 0.001 1.3 1.0, 1.8 < 0.001
Age at recruitment (N = 2713)
< 30 years¶ 103 3.8 29/99 29.3 1 1
30–39 years 569 21.0 105/550 19.1 0.7 0.5, 0.9 0.8 0.6, 1.1
40–49 years 1204 44.4 170/1157 14.7 0.5 0.4, 0.7 0.7 0.5, 0.9
50–59 years 640 23.6 84/632 13.3 0.5 0.3, 0.7 0.7 0.5, 1.0
≥ 60 years 197 7.3 31/189 16.4 0.6 0.4, 0.9 0.002 (t) 0.8 0.5, 1.2 0.16 (t)
Ethnicity (N = 2771)
White¶ 1894 68.4 231/1854 12.5 1 1
Black African 533 19.2 134/498 26.9 2.2 1.8, 2.6 1.5 1.2, 2.0
Black Caribbean
or black other
94 3.4 20/89 22.5 1.8 1.2, 2.7 1.4 0.9, 2.1
Other/missing 250 9.0 49/237 20.7 1.7 1.3, 2.2 < 0.001 1.4 1.0, 1.8 0.015
UK birth/fluency in spoken English (N = 2684)
Born in the UK¶ 1529 57.0 185/1491 12.4 1 1.0
Non-UK born,
fluent in spoken English
899 33.5 147/871 16.9 1.4 1.1, 1.7 1.0 0.8, 1.3
Non-UK born, speaks
English quite well
233 8.7 70/215 32.6 2.6 2.1, 3.3 1.7 1.3, 2.3
Non-UK born, speaks
English not at all well
23 0.9 17/23 73.9 6.0 4.5, 7.9 < 0.001 (t) 3.5 2.4, 5.1 < 0.001 (t)
Education (N = 2696)
University education¶ 1115 41.4 115/1084 10.6 1 1
A levels/O levels or
equivalent; other
nonuniversity
1274 47.3 218/1237 17.6 1.7 1.3, 2.1 1.6 1.3, 2.0
No educational
qualifications
307 11.4 90/291 30.9 2.9 2.3, 3.7 < 0.001 (t) 2.7 2.1, 3.4 < 0.001 (t)
Employment status (N = 2699)
Employed (full or part-time)¶ 1509 55.9 182/1461 12.5 1 1
Unemployed 496 18.4 118/477 24.7 2.0 1.6, 2.4 1.7 1.4, 2.1
Not working because of
sickness/disability
380 14.1 63/370 17.0 1.4 1.1, 1.8 1.6 1.3, 2.1
Retired 180 6.7 25/174 14.4 1.2 0.8, 1.7 1.3 0.8, 2.0
Other (looking after home/
family, carer, student or other)
134 5.0 32/131 24.4 2.0 1.4, 2.7 < 0.001 1.4 1.0, 2.0 < 0.001
Housing (N = 2720)
Homeowner¶ 959 35.3 91/938 9.7 1 1
Renting (council or housing
association)
1482 54.5 255/1431 17.8 1.8 1.5, 2.3 1.5 1.2, 1.9
Unstable/other (temporary,
staying with friends or homeless)
279 10.3 79/261 30.3 3.1 2.4, 4.1 < 0.001 (t) 2.1 1.6, 2.8 < 0.001 (t)
Money for basic needs, e.g. food and heating (N = 2717)
Always¶ 1189 43.8 121/1160 10.4 1 1
Mostly 708 26.1 104/692 15.0 1.4 1.1, 1.8 1.4 1.1, 1.7
Sometimes 483 17.8 103/461 22.3 2.1 1.7, 2.7 1.8 1.4, 2.3
No 337 12.4 97/315 30.8 3.0 2.3, 3.7 < 0.001 (t) 2.4 1.9, 3.1 < 0.001 (t)
Low supportive network (score ≤ 12; modified Duke FSSQ) (N = 2731)
No¶ 2343 85.8 349/2268 15.4 1 1
Yes 388 14.2 75/377 19.9 1.3 1.0, 1.6 0.041 1.4 1.1, 1.7 0.016
Partner status (N = 2752)
HIV-positive stable partner¶ 660 24.0 88/633 13.9 1 1
HIV-negative or
unknown status stable partner
905 32.9 128/878 14.6 1.0 0.8, 1.3 1.0 0.8, 1.3
© 2016 The Authors.
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76 (22.1%) incorrectly self-reported that their VL was
undetectable, and 85 (24.7%) did not know their VL. Of
all 2137 individuals who self-reported an undetectable
VL, the vast majority (2061; 96.4%) had clinic-recorded
VL ≤ 50 copies/mL; among the remaining 76 individu-
als, clinic-recorded VL was 51–199 copies/mL for 48;
200–999 copies/mL for 13; ≥ 1000 copies/mL for 15.
Therefore the prevalence of clinic-recorded VL<1000
copies/mL among those with self-reported undetectable
VL was 99.3% (2122/2137). Overall, agreement between
an individual’s self-reported VL status and clinic-
recorded VL was demonstrated in 2244 (83.8%) of HIV-
positive people on ART, and disagreement (including
“don’t know”) in 434 (16.2%) individuals.
Agreement between self-reported and clinic-recorded
CD4 count
Among 2771 participants on ART, the clinic-recorded
CD4 count was not documented for 19 participants, and
was dated after questionnaire issue for a further 15. In
addition, 70 individuals did not respond to the self-
Table 1 (Continued )
Prevalence (N = 2771)*
Inaccurate self-report of clinic
viral load† (n/N = 434/2678)‡ Unadjusted PR and 95% CI§ Adjusted PR and 95% CI§
N % n/N Row % PR 95% CI P-value PR 95% CI P-value
No stable partner 1187 43.1 216/1150 18.8 1.4 1.1, 1.7 0.008 1.4 1.1, 1.8 0.001
Disclosed HIV status? (other than to health care staff) (N = 2754)
Yes¶ 2536 92.1 362/2464 14.7 1 1
No 218 7.9 64/199 32.2 2.2 1.8, 2.7 < 0.001 1.7 1.3, 2.1 < 0.001
Time since clinic-recorded VL result (N = 2742)
≤ 1 month¶ 889 32.4 125/874 14.3 1 1
1–6 months 1601 58.4 263/1564 16.8 1.2 1.0, 1.4 1.1 0.9, 1.4
> 6 months 252 9.2 46/240 19.2 1.3 1.0, 1.8 0.039 (t) 1.3 1.0, 1.7 0.073 (t)
Time since started ART (N = 2681)
≤ 6 months¶ 166 6.2 51/159 32.1 1 1
6 months to 1 year 104 3.9 20/102 19.6 0.6 0.4, 1.0 0.6 0.4, 1.0
1–2 years 191 7.1 28/175 16.0 0.5 0.3, 0.8 0.5 0.3, 0.8
2–5 years 531 19.8 89/521 17.1 0.5 0.4, 0.7 0.6 0.4, 0.7
5–10 years 710 26.5 107/683 15.7 0.5 0.4, 0.6 0.5 0.4, 0.7
> 10 years 979 36.5 107/958 11.2 0.3 0.3, 0.5 < 0.001 (t) 0.4 0.3, 0.6 < 0.001(t)
ART adherence: ART doses missed in past 2 weeks (N = 2756)
None¶ 2068 75.0 293/2006 14.6 1 1
One 370 13.4 59/358 16.5 1.1 0.9, 1.5 1.2 0.9, 1.5
Two 160 5.8 32/154 20.8 1.4 1.0, 2.0 1.5 1.1, 2.1
Three or more 158 5.7 46/150 30.7 2.1 1.6, 2.7 < 0.001 (t) 2.1 1.7, 2.7 < 0.001 (t)
ART adherence: ever missed two consecutive days of ART in past 3 months? (N = 2757)
No¶ 2283 82.8 322/2209 14.6 1 1
Yes, once 155 5.6 25/151 16.6 1.1 0.8, 1.6 1.1 0.8, 1.6
Yes, two to three times 199 7.2 47/193 24.4 1.7 1.3, 2.2 1.5 1.2, 2.0
Yes, more than three times 120 4.4 37/114 32.5 2.2 1.7, 3.0 < 0.001 (t) 2.2 1.6, 2.9 < 0.001 (t)
Depressive symptoms (PHQ-9 score ≥ 10) (N = 2771)
No¶ 2023 73.0 265/1955 13.6 1 1
Yes 748 27.0 169/723 23.4 1.7 1.5, 2.1 < 0.001 1.9 1.6, 2.2 < 0.001
Anxiety symptoms (GAD-7 score ≥ 10) (N = 2771)
No¶ 2154 77.7 301/2082 14.5 1 1
Yes 617 22.3 133/596 22.3 1.5 1.3, 1.9 < 0.001 1.6 1.3, 1.9 < 0.001
Treatment (medical or other) for depression (N = 2771)
No¶ 2206 79.6 334/2133 15.7 1 1
Yes 565 20.4 100/545 18.3 1.2 1.0, 1.4 0.14 1.3 1.1, 1.6 0.013
MSM, men who have sex with men; CI, confidence interval; FSSQ, Functional Social Support Questionnaire; PR, prevalence ratio; PHQ-9, Patient Health
Questionnaire, 9 item scale; GAD-7, Generalized Anxiety Disorder 7 item scale; (t), test for linear trend across categories performed.
For explanatory variables with missing values for > 30 participants, the prevalence of inaccurate self-report among the subgroup with a missing value
ranged from 16.7% (among those with missing education status) to 40.0% (among those with missing time since started ART).
*Prevalence among participants on ART at the time of the questionnaire.
†Disagreement between clinic-recorded and self-reported undetectable VL status, or “don’t know” response for self-report.
‡Analysis excludes 93 of 2771 individuals on ART. Exclusions were: missing clinic-recorded viral load (n = 18); clinic-recorded viral load dated after
questionnaire issue (n = 11); missing self-reported viral load (n = 64).
§Unadjusted and adjusted prevalence ratios and 95% confidence intervals using modified Poisson regression. For adjusted analyses, each factor is
included in a separate model and adjusted for “gender/sexual orientation”, “age group”, “ethnicity” and “time since started ART group”. Denominators
are equivalent for unadjusted and adjusted analyses, as in multivariable models, “age group” and “time since started ART” were fitted using a “missing”
category (n = 51 and n = 80 missing values, respectively). P values were obtained using the score statistic.
¶Reference category.
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reported CD4 question. Of the remaining 2667 partici-
pants, 2183 (81.9%) had a clinic-recorded CD4 count
> 350 cells/lL (Table 2b). Of the 484 participants with a
clinic CD4 count ≤ 350 cells/lL, 370 (76.4%) correctly
self-reported a CD4 count ≤ 350 cells/lL, 65 (13.4%)
incorrectly self-reported that their CD4 count was
> 350 cells/lL, and 49 (10.1%) self-reported “don’t
know”. Of 2183 participants with a CD4 count of
> 350 cells/lL, 1685 (77.2%) correctly self-reported a
CD4 count > 350 cells/lL; 266 (12.2%) incorrectly self-
reported that their CD4 count was ≤ 350 cells/lL; 232
(10.6%) responded “don’t know”. Overall agreement
between an individual’s self-report and the clinical record
of the level of CD4 count was demonstrated in 2055
(77.1%) of HIV-positive people on ART and disagreement
(including “don’t know”) in 612 (22.9%).
Demographic and socioeconomic factors and accuracy
of self-reported VL
In unadjusted analysis, demographic characteristics
associated with inaccurate self-report of VL were:
Table 2 (a) Agreement between clinic-record and self-report for: (a) HIV viral load level among 2678 HIV-diagnosed participants on antiretro-
viral therapy (ART)* and (b) CD4 count level among 2667 HIV-diagnosed participants on ART†
(a)
All participants (N = 2678)
Self-reported latest viral load
Clinic-recorded viral load (latest result available to participant)
≤ 50 copies/mL (N = 2334) > 50 copies/mL (N = 344)
n Column % Row % n Column % Row %
≤ 50 copies/mL‡ (N = 2137) 2061 88.3 96.4 76 22.1 3.6
> 50 copies/mL§ (N = 232) 49 2.1 21.1 183 53.2 78.9
Don’t know (N = 309) 224 9.6 72.5 85 24.7 27.5
MSM (N = 1852)
Self-reported latest viral load
≤ 50 copies/mL (N = 1638) > 50 copies/mL (N = 214)
n Column % Row % n Column % Row %
≤ 50 copies/mL‡ (N = 1555) 1500 91.6 96.5 55 25.7 3.5
> 50 copies/mL§ (N = 157) 30 1.8 19.1 127 59.3 80.9
Don’t know (N = 140) 108 6.6 77.1 32 15.0 22.9
Heterosexual men and women (N = 826)
Self-reported latest viral load
≤ 50 copies/mL (N = 696) > 50 copies/mL (N = 130)
n Column % Row % n Column % Row %
≤ 50 copies/mL‡ (N = 582) 561 80.6 96.4 21 16.2 3.6
> 50 copies/mL§ (N = 75) 19 2.7 25.3 56 43.1 74.7
Don’t know (N = 169) 116 16.7 68.6 53 40.8 31.4
(b)
All participants (N = 2667)
Self-reported CD4 count (cells/lL)
Clinic-recorded CD4 count (cells/lL) (latest result available to participant)
≤ 350 (N = 484) > 350 (N = 2183)
n Column % Row % n Column % Row %
< 200 (N = 258) 132 27.3 51.2 126 5.8 49.8
200–350 (N = 378) 238 49.2 63.0 140 6.4 37.0
351–500 (N = 632) 56 11.6 8.9 576 26.4 91.1
> 500 (N = 1118) 9 1.9 0.8 1109 50.8 99.2
Don’t know (N = 281) 49 10.1 17.4 232 10.6 82.6
MSM (N = 1840)
Self-reported CD4 count (cells/lL)
≤ 350 (N = 282) > 350 (N = 1558)
n Column % Row % n Column % Row %
< 200 (N = 156) 80 28.4 51.3 76 4.9 48.7
200–350 (N = 257) 155 55.0 60.3 102 6.5 39.7
351–500 (N = 458) 29 10.3 6.3 429 27.5 93.7
> 500 (N = 845) 7 2.5 0.8 838 53.8 99.2
Don’t know (N = 124) 11 3.9 8.9 113 7.3 91.1
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gender/sexual orientation (women and heterosexual
men were more likely to have inaccurate self-report
compared with MSM), younger age (those < 30 years
old were more likely to have inaccurate self-report
compared with all other age groups) and nonwhite eth-
nicity (Table 1). There were striking associations with
socioeconomic factors: non-UK birth/low English flu-
ency, nonuniversity education, nonemployment (other
than retirement), being in rented or unstable housing,
and greater financial hardship were strongly associated
with a higher prevalence of inaccurate self-report. Low
supportive network was also associated with inaccurate
self-report. In analyses adjusted for gender/sexual
orientation, age group, ethnicity, and time since started
ART group, most associations were attenuated, but indi-
cators of socioeconomic disadvantage remained strongly
associated with inaccurate self-report (Table 1). For
example, those who did not have enough money for
basic needs had more than twice the prevalence of
incorrectly self-reporting their VL status compared with
those who always had enough money. Similarly, com-
pared with those who owned their own home, those in
unstable accommodation had twice the prevalence of
incorrectly self-reporting their VL status. Those who
were non-UK born and reported poor English fluency
had more than three times the prevalence of incorrectly
self-reporting their VL status compared with those born
in the UK (which may in part reflect difficulties with
comprehension of the question on the latest VL level).
Gender/sexual orientation and ethnicity were indepen-
dently associated with inaccurate self-report in the
model including both factors together with age group
and time since started ART group, but associations
were attenuated.
HIV-related factors and accuracy of self-reported VL
In unadjusted analyses, not having a stable partner and
nondisclosure of HIV status were associated with inaccu-
rate self-report of VL. A shorter time since starting ART
was strongly associated with inaccurate self-report, with
a particularly high prevalence among those who had very
recently started ART (when VL level is likely to be chang-
ing rapidly). Self-reported nonadherence to ART was also
strongly associated with inaccurate self-report: for exam-
ple, the prevalence was twice as high among those who
missed three or more doses in the past 2 weeks compared
with those who reported no missed doses. The prevalence
of inaccurate self-report was also somewhat higher for
those whose latest VL results were > 6 months ago com-
pared with more recent. These associations were similar
after adjustment for gender/sexual orientation, ethnicity,
age group and time since started ART group (Table 1).
Mental health and accuracy of self-reported VL
Depression symptoms and anxiety symptoms were
strongly associated with inaccurate self-report in unad-
justed and adjusted analyses. For example, in the
adjusted analysis, the prevalence of inaccurate self-report
was increased approximately twofold for those with cur-
rent depressive symptoms. Treatment for depression was
also associated with inaccurate self-report in the adjusted
analysis (Table 1).
Sensitivity analysis
When participants who did not provide an answer to the
question on self-reported VL (n = 64) were included in
Table 2 (Continued )
Clinic-recorded CD4 count (cells/lL) (latest result available to participant)
Heterosexual men and women (N = 827)
Self-reported CD4 count (cells/lL)
≤ 350 (N = 202) > 350 (N = 625)
n Column % Row % n Column % Row %
< 200 (N = 102) 52 25.7 51.0 50 8.0 49.0
200–350 (N = 121) 83 41.1 68.6 38 6.1 31.4
351–500 (N = 174) 27 13.4 15.5 147 23.5 84.5
> 500 (N = 273) 2 1.0 0.7 271 43.4 99.3
Don’t know (N = 157) 38 18.8 24.2 119 19.0 75.8
MSM, men who have sex with men.
*The analysis excludes 93 of 2771 individuals on ART. Exclusions were: missing clinic-recorded viral load (n = 18); clinic-recorded viral load dated after
questionnaire issue (n = 11); missing self-reported viral load (n = 64).
†The analysis excludes 104 of 2771 individuals on ART. Exclusions were: missing clinic-recorded CD4 count (n = 19); clinic-recorded CD4 count dated
after questionnaire issue (n = 15); missing self-reported CD4 count (n = 70).
‡50 copies/mL or less (‘undetectable’ or ‘suppressed’).
§
More than 50 copies/mL (‘detectable’ or ‘raised’).
© 2016 The Authors.
HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
HIV Medicine (2017), 18, 463--473
Accuracy of self-reported HIV viral load 469
the “disagreement” category, the proportion of partici-
pants with inaccurate self-report of VL was 18.2% (498
of 2742). When 70 participants with missing self-report
of CD4 count level were classified as “disagreement”, the
proportion of participants with inaccurate self-report of
CD4 count level was 24.9% (682 of 2737). Associations
of factors with inaccurate self-report of VL were very
similar to those found in the main analysis (results not
shown).
Discussion
We report on levels of agreement between self-report and
clinic-recorded laboratory values of VL and CD4 count in
people treated for HIV infection in the UK. A minority
(16%) of HIV-positive individuals on ART did not cor-
rectly self-report whether their VL was undetectable. A
quarter (25.0%) of HIV-positive individuals on ART did
not correctly self-report their CD4 count within broad
categories. Heterosexual male and female gender/sexual
orientation, non-white ethnicity, lower socioeconomic
status, poor English fluency, low supportive network, not
having a stable partner, nondisclosure of HIV status, hav-
ing recently started ART, ART nonadherence and poorer
mental health were associated with inaccurate self-report
of VL.
To our knowledge, this is the first European study to
assess agreement between self-reported and clinic-
recorded HIV VL and CD4 count. Our findings are compa-
rable to those of several studies assessing accuracy of
reporting of HIV biomarkers in people with HIV in the
USA, most of which found overall moderate levels of
agreement between self-report and medical record, and
which found evidence that younger age, lower education,
lower health literacy and socioeconomic disadvantage
were associated with inaccurate self-report of VL and
CD4 count [24–28]. Our results suggest that, even in a UK
setting with free access to health care and treatment,
socioeconomic disadvantage is strongly linked to lack of
knowledge of HIV-related markers.
HIV is a life-long, chronic condition and proficient
knowledge of HIV health markers among people with
HIV infection supports self-management, which can
impact on engagement and retention in care [29]. Rea-
sons for lack of knowledge of personal VL level in those
with disadvantaged socioeconomic circumstances are
likely to be complex and multifaceted. Lower levels of
knowledge could in part be a consequence of health
ranking as a lower priority in the context of immediate
pressures. For example, financial, housing, employment
or family difficulties may result in prioritization of these
issues above personal health. This may impact on
attendance at, or engagement with, health services. For
patients who are non-UK born with lower English flu-
ency, this language barrier alone can result in anxiety
and stress at clinic appointments, and make clinic inter-
actions difficult and thus harder to engage with. Our
study suggests that those with a lower level of education
are also less likely to have accurate knowledge of their
VL status, which may be linked to health literacy, and
may also make HIV appointments stressful or confusing,
and potentially reduce motivation to attend. Depression
and other mental health problems may adversely impact
on motivation and prioritization of HIV-related health.
The results could also be interpreted as showing that
health providers are less successful in actively engaging
HIV-positive people who have more complex needs in
their own health care. Possible strategies to improve such
engagement may include having clearer explanations
after diagnosis about the importance of CD4 count and
VL and what they mean for care, and having printed
resources in languages other than English with involve-
ment of peer advocates who speak the mother languages.
In addition, greater training and resources on these issues
for health professionals themselves may be needed. It is
also important to note that lack of knowledge of personal
VL level may be related to the approach taken by a doc-
tor in discussing results with a patient. Specific values of
laboratory test results may not always be given to all
patients, a strategy that could be viewed as appropriate
in some circumstances. In some cases, doctors may only
communicate results if there is something to be con-
cerned about. For example “undetectable viral load”, or
an exact value of the CD4 count, might not be directly
explained by a doctor if they think their patient would
prefer a more general summary of HIV health status. A
doctor might choose instead perhaps to emphasize adher-
ence and say that generally everything is okay. Insights
into this level of patientdoctor communication are
beyond the scope of this study.
Defining engagement in care is complex, and requires
more than a single measure of appointment attendance
[30–33]. One previous study from the USA used multiple
markers including knowledge of personal CD4 count
and antiretroviral treatment, medication adherence, and
appointment attendance, to form a composite measure
of engagement [30]. In our study, knowledge of
personal VL level was strongly associated with ART
adherence. Previous studies have found that greater
engagement with care was associated with higher preva-
lence of viral suppression [30,33]. Further investigation
of self-knowledge of VL as a predictor of engagement
in care could help identify those patients at risk of
becoming disengaged.
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Strong evidence now demonstrates that viral suppres-
sion as a result of ART substantially reduces infectious-
ness of HIV-positive people to sexual partners [11–17].
Further evidence indicates that some MSM may use viral
suppression in decision-making about condomless sex
[34–38]. In the ASTRA study, there was evidence that
knowledge of suppressed VL impacted on condom use
among MSM, although the effect was modest at the time
of the study, and was not apparent for heterosexual men
and women [38]. The accuracy of reporting an unde-
tectable VL by HIV-positive individuals on ART is
directly relevant for their HIV-negative sexual partners, if
the HIV-positive partner’s VL influences decision-making
around condom use. The high level of accuracy of a self-
reported undetectable VL found in this UK study is
encouraging, as this implies that decisions to have con-
domless sex on this basis will generally be well informed.
Of all participants who self-reported undetectable VL,
< 4% did not have a VL ≤ 50 copies/mL. Furthermore,
among this subset who incorrectly reported an unde-
tectable VL, the majority had a clinic-recorded value
< 1000 copies/mL, making HIV transmission very unli-
kely. However, it is important to recognize that the
prevalence of VL suppression (both overall and among
those with self-reported undetectable VL) and awareness
of personal VL level may be overestimated in our study
as it was conducted among HIV-positive individuals
attending clinic and who agreed to participation, suggest-
ing a degree of engagement in care. As ART use expands
and knowledge about the protective effect of ART on HIV
transmission is publicized and disseminated, further
attention should be paid to ensure that all HIV-positive
people on ART are able to correctly self-report whether
their latest HIV VL is undetectable. The importance of
ART adherence and regular VL testing for those with
HIV-negative sexual partners should also be emphasized
in this context.
A strength of the ASTRA study is that it included a
large, unselected sample of people with diagnosed HIV
infection in the UK, in contrast to similar studies on
this topic from the USA that have mainly been con-
ducted among low-income or hard-to-reach popula-
tions and had smaller sample sizes. [24–28]. Our study
has some limitations. Knowledge of HIV biomarkers
may have been overestimated if such knowledge was
poorer among study nonresponders, those not eligible
for the study because of language difficulties, those
without the opportunity to be invited because of very
infrequent clinic attendance, or the small number of
participants who had missing data on ART status.
Although study personnel were asked to record the
latest clinic values of VL and CD4 that had been
communicated to the participant, accuracy of self-
report may be underestimated if cases of disagreement
were attributable to participants recalling VL test
results from a different date from the clinic-recorded
test.
Our results demonstrate high accuracy of a self-
report of undetectable VL among people receiving ART
in the UK. Overall accuracy of self-report varied
according to demographic, socioeconomic, HIV and
health-related factors. Indicators of socioeconomic dis-
advantage, nondisclosure of HIV status, poorer ART
adherence, and poorer mental health were strongly
linked to inaccurate knowledge of VL. We identify a
need for a stronger clinical focus on a specific group
of patients, characterized by adverse socioeconomic cir-
cumstances, to improve their knowledge and experience
of HIV care, as well as those with limited English who
should be routinely offered access to interpreter ser-
vices. Accurate knowledge of VL is important at both
an individual and a public health level. Further consi-
deration should be given to including it as part of a
composite tool to measure engagement in care, together
with a clinic plan for subsequent interventions to sup-
port people who are not engaged.
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